Business
Ainos Reports Statistically Significant Interim Efficacy Results from VELDONA Clinical Trial in Feline Chronic Gingivostomatitis (FCGS)
Open-Label Study Demonstrates Durable Reduction in Oral Inflammation with Favorable Tolerability Profile at Interim Analysis HOUSTON, TEXAS / ACCESS Newswire / February 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), ...
About this update from Ainos, Inc.
[{"type":"text","content":"Open-Label Study Demonstrates Durable Reduction in Oral Inflammation with Favorable Tolerability Profile at Interim Analysis","length":124,"tagName":"p"},{"type":"text","content":"HOUSTON, TEXAS / ACCESS Newswire / February 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced interim results from its ongoing open-label, multi-dose clinical trial evaluating VELDONA, a low-dose oral interferon alpha formulation, for the treatment of Feline Chronic Gingivostomatitis (FCGS), a severe, chronic inflammatory oral disease in companion animals.","length":524,"tagName":"p"},{"type":"text","content":"The study is designed to enroll 12 client-owned cats diagnosed with FCGS across two dosing cohorts (6,000 IU and 12,000 IU administered orally three times per week for six weeks). The interim analysis includes the first six treated subjects. Enrollment remains ongoing.","length":269,"tagName":"p"},{"type":"text","content":"Interim Efficacy Results","length":24,"tagName":"p"},{"type":"text","content":"The primary disease activity assessment utilized the Stomatitis Disease Activity Index (SDAI; range 0-30), a composite score integrating:","length":137,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Veterinary assessment of oral inflammation","length":42,"tagName":"p"}]},{"val":[{"type":"text","content":"Body weight changes","length":19,"tagName":"p"}]},{"val":[{"type":"text","content":"Owner-reported activity and feeding behavior","length":44,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":105,"olType":false},{"type":"text","content":"At Week 6:","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The majority of subjects demonstrated reductions in total SDAI scores.","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Directional improvement in overall disease activity was observed across the cohort.","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"No clinically significant rebound was observed through Week 14 follow-up.","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":226,"olType":false},{"type":"text","content":"Local oral inflammation scores demonstrated consi...